{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=One+cycle&page=21", "query": { "intervention": "One cycle", "page": 21 }, "page_size": 10 }, "pagination": { "page": 21, "page_size": 10, "total_count": 2770, "total_pages": 277, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=One+cycle&page=22&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=One+cycle&page=20&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-26T23:15:43.917Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01211691", "title": "Study of KB004 in Subjects With Hematologic Malignancies (Myelodysplastic Syndrome, MDS, Myelofibrosis, MF)", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Myelodysplastic Syndrome (MDS)", "Myelofibrosis (MF)" ], "interventions": [ { "name": "KB004, Monoclonal Antibody", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Humanigen, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2010-09", "completion_date": "2016-12", "has_results": false, "last_update_posted_date": "2015-11-17", "last_synced_at": "2026-10-26T23:15:43.917Z", "location_count": 7, "location_summary": "Palo Alto, California • Sacramento, California • Miami, Florida + 4 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Manhattan", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01211691" }, { "nct_id": "NCT01972516", "title": "Tivozanib As Maintenance Therapy In GYN", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Cancer", "Fallopian Tube Cancer", "Primary Peritoneal Carcinoma" ], "interventions": [ { "name": "Tivozanib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 4, "start_date": "2013-11", "completion_date": "2016-01", "has_results": true, "last_update_posted_date": "2017-06-05", "last_synced_at": "2026-10-26T23:15:43.917Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01972516" }, { "nct_id": "NCT00691015", "title": "Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Myeloproliferative Disorders", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Neoplasms" ], "interventions": [ { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "busulfan", "type": "DRUG" }, { "name": "carmustine", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "total body irradiation (TBI)", "type": "RADIATION" }, { "name": "anti-thymocyte globulin IV", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "Barbara Ann Karmanos Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2008-05", "completion_date": "2014-04", "has_results": true, "last_update_posted_date": "2017-06-28", "last_synced_at": "2026-10-26T23:15:43.917Z", "location_count": 1, "location_summary": "Detroit, Michigan", "locations": [ { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00691015" }, { "nct_id": "NCT06843447", "title": "A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Ovarian Cancer Recurrent" ], "interventions": [ { "name": "Raludotatug Deruxtecan", "type": "BIOLOGICAL" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Rescue Medication", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Pegylated liposomal doxorubicin", "type": "DRUG" }, { "name": "MK-2010", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 605, "start_date": "2025-04-15", "completion_date": "2031-02-07", "has_results": false, "last_update_posted_date": "2026-10-21", "last_synced_at": "2026-10-26T23:15:43.917Z", "location_count": 10, "location_summary": "New Haven, Connecticut • Louisville, Kentucky • Shreveport, Louisiana + 7 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Shreveport", "state": "Louisiana" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06843447" }, { "nct_id": "NCT05450432", "title": "Long-Term Maintenance With Ketamine and Esketamine for Reduction of Suicide in High-Risk Patients With Depression", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Major Depressive Disorder" ], "interventions": [ { "name": "Ketamine", "type": "DRUG" }, { "name": "Esketamine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 100, "start_date": "2022-10-13", "completion_date": "2026-06-01", "has_results": false, "last_update_posted_date": "2025-12-12", "last_synced_at": "2026-10-26T23:15:43.917Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05450432" }, { "nct_id": "NCT04668885", "title": "CPX-351 as a Novel Approach for the Treatment of Older Patients With AML and MDS", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Refractory Acute Myeloid Leukemia", "Relapsed Acute Myelomonocytic Leukemia", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "CPX-351", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 13, "start_date": "2021-01-14", "completion_date": "2027-01-19", "has_results": false, "last_update_posted_date": "2026-06-12", "last_synced_at": "2026-10-26T23:15:43.917Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04668885" }, { "nct_id": "NCT01872715", "title": "Patient Centered Outcomes in Rosacea: An Exploratory Multi-media Analysis of the Patient Experience on Oracea", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Papulopustular Rosacea" ], "interventions": [ { "name": "Oracea", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Galderma R&D", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "25 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "25 Years to 70 Years" }, "enrollment_count": 24, "start_date": "2013-03", "completion_date": "2013-06", "has_results": true, "last_update_posted_date": "2022-08-23", "last_synced_at": "2026-10-26T23:15:43.917Z", "location_count": 1, "location_summary": "Carrollton, Texas", "locations": [ { "city": "Carrollton", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01872715" }, { "nct_id": "NCT04549935", "title": "The PRIME Study: A Randomized, Controlled, Prospective Study", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Patient Preference", "Patient Outcomes", "Post-Operative Inflammation", "Grade of Post-Operative Cystoid Macular Edema", "Rate of Post-Operative Cystoid Macular Edema" ], "interventions": [ { "name": "Dextenza", "type": "DRUG" }, { "name": "Topical Prednisolone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vance Thompson Vision - MT", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "22 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "22 Years to 75 Years" }, "enrollment_count": 20, "start_date": "2020-09-14", "completion_date": "2021-08-27", "has_results": false, "last_update_posted_date": "2020-09-16", "last_synced_at": "2026-10-26T23:15:43.917Z", "location_count": 1, "location_summary": "Bozeman, Montana", "locations": [ { "city": "Bozeman", "state": "Montana" } ], "official_url": "https://clinicaltrials.gov/study/NCT04549935" }, { "nct_id": "NCT00679835", "title": "PK and Safety Evaluation of Daptomycin in Children Ages 2-6 With Proven or Suspected Gram-positive Infections", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Gram Positive Infection", "Concurrent Antibiotic Treatment" ], "interventions": [ { "name": "daptomycin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "6 Years", "sex": "ALL", "summary": "2 Years to 6 Years" }, "enrollment_count": 24, "start_date": "2008-06-03", "completion_date": "2008-11-20", "has_results": false, "last_update_posted_date": "2019-11-13", "last_synced_at": "2026-10-26T23:15:43.917Z", "location_count": 1, "location_summary": "Kansas City, Missouri", "locations": [ { "city": "Kansas City", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT00679835" }, { "nct_id": "NCT03456986", "title": "Improvements in Cognitive Skills of Older Adults Using Dynamic Visual Attention Training", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Age Related Cognitive Decline" ], "interventions": [ { "name": "PATH neurotraining", "type": "BEHAVIORAL" }, { "name": "Orientation Discrimination", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Perception Dynamics Institute", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "55 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "55 Years to 75 Years" }, "enrollment_count": 0, "start_date": "2018-09-04", "completion_date": "2021-09-30", "has_results": false, "last_update_posted_date": "2020-03-04", "last_synced_at": "2026-10-26T23:15:43.917Z", "location_count": 2, "location_summary": "La Jolla, California • Solana Beach, California", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Solana Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03456986" } ] }